001     141725
005     20240229112525.0
024 7 _ |a 10.1093/cvr/cvy274
|2 doi
024 7 _ |a pmid:30418544
|2 pmid
024 7 _ |a 0008-6363
|2 ISSN
024 7 _ |a 1755-3245
|2 ISSN
024 7 _ |a altmetric:62570970
|2 altmetric
037 _ _ |a DKFZ-2018-01994
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Müller, Oliver J
|b 0
245 _ _ |a Comprehensive plasma and tissue profiling reveals systemic metabolic alterations in cardiac hypertrophy and failure.
260 _ _ |a Oxford
|c 2019
|b Oxford University Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1562837967_13831
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Heart failure is characterized by structural and metabolic cardiac remodelling. The aim of the present study is to expand our understanding of the complex metabolic alterations in the transition from pathological hypertrophy to heart failure and exploit the results from a translational perspective.Mice were subjected to transverse aortic constriction (TAC) or sham surgery and sacrificed 2, 4, or 6 weeks after the procedure. Samples from plasma, liver, skeletal muscle, and heart were collected and analysed using metabolomics. Cardiac samples were also analysed by transcriptional profiling. Progressive alterations of key cardiac metabolic pathways and gene expression patterns indicated impaired mitochondrial function and a metabolic switch during transition to heart failure. Similar to the heart, liver and skeletal muscle revealed significant metabolic alterations such as depletion of essential fatty acids and glycerolipids in late stages of heart failure. Circulating metabolites, particularly fatty acids, reflected cardiac metabolic defects and deteriorating heart function. For example, inverse correlation was found between plasma and the heart levels of triacylglycerol (C18:1, C18:2, C18:3), and sphingomyelin (d18:1, C23:0) already at an early stage of heart failure. Interestingly, combining metabolic and transcriptional data from cardiac tissue revealed that decreased carnitine shuttling and transportation preceded mitochondrial dysfunction. We, thus, studied the therapeutic potential of OCTN2 (Organic Cation/Carnitine Transporter 2), an important factor for carnitine transportation. Cardiac overexpression of OCTN2 using an adeno-associated viral (AAV) vector significantly improved ejection fraction and reduced interstitial fibrosis in mice subjected to TAC.Comprehensive plasma and tissue profiling reveals systemic metabolic alterations in heart failure, which can be used for identification of novel biomarkers and potential therapeutic targets.
536 _ _ |a 317 - Translational cancer research (POF3-317)
|0 G:(DE-HGF)POF3-317
|c POF3-317
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Heckmann, Markus B
|b 1
700 1 _ |a Ding, Lin
|b 2
700 1 _ |a Rapti, Kleopatra
|b 3
700 1 _ |a Rangrez, Ashraf Y
|b 4
700 1 _ |a Gerken, Thomas
|b 5
700 1 _ |a Christiansen, Nicole
|b 6
700 1 _ |a Rennefahrt, Ulrike E E
|b 7
700 1 _ |a Witt, Henning
|b 8
700 1 _ |a Maldonado, Sandra González
|b 9
700 1 _ |a Ternes, Philipp
|b 10
700 1 _ |a Schwab, Dominic M
|b 11
700 1 _ |a Ruf, Theresa
|b 12
700 1 _ |a Hille, Susanne
|b 13
700 1 _ |a Remes, Anca
|b 14
700 1 _ |a Jungmann, Andreas
|b 15
700 1 _ |a Weis, Tanja M
|b 16
700 1 _ |a Kreußer, Julia
|b 17
700 1 _ |a Gröne, Hermann-Josef
|0 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91
|b 18
|u dkfz
700 1 _ |a Backs, Johannes
|b 19
700 1 _ |a Schatz, Philipp
|b 20
700 1 _ |a Katus, Hugo A
|b 21
700 1 _ |a Frey, Norbert
|b 22
773 _ _ |a 10.1093/cvr/cvy274
|0 PERI:(DE-600)1499917-1
|n 8
|p 1296-1305
|t Cardiovascular research
|v 115
|y 2019
|x 1755-3245
909 C O |o oai:inrepo02.dkfz.de:141725
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 18
|6 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-317
|2 G:(DE-HGF)POF3-300
|v Translational cancer research
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CARDIOVASC RES : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b CARDIOVASC RES : 2017
920 1 _ |0 I:(DE-He78)G130-20160331
|k G130
|l Zelluläre und Molekulare Pathologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G130-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21